Every 10-Q that Structure Therapeutics Inc. American (GPCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPCR filings page.
Structure Therapeutics Inc., a clinical-stage biopharma focused on oral GPCR-targeted drugs for obesity and related diseases, reported a net loss of $106.2 million for Q2 2026 and $182.1 million for the first half, driven mainly by higher research and development spending.
R&D expenses were $100.1 million in Q2 and $166.6 million year-to-date, reflecting Phase 2 and Phase 3 work on oral GLP‑1 agonist aleniglipron and amylin programs. General and administrative costs were $18.6 million in Q2, while interest and other income contributed $26.3 million in H1.
As of June 30 2026, cash, cash equivalents and short-term investments totaled $1,342.7 million, with an accumulated deficit of $652.4 million. The company states this liquidity should fund projected operations and key clinical milestones, including the Phase 3 ACCOMPLISH program for aleniglipron, through the end of 2028.
Structure Therapeutics Inc. reported a wider quarterly loss as it ramps obesity drug development but remains very well funded. For the three months ended March 31, 2026, net loss was $75.97 million, or $0.35 per share, compared with $46.83 million a year earlier. Research and development spending rose to $66.51 million and general and administrative expenses to $22.87 million, reflecting expanded clinical programs and headcount.
The company ended the quarter with $1.46 billion in cash, cash equivalents and short-term investments and total shareholders’ equity of $1.45 billion, giving it substantial resources to fund trials. Management states this cash should support operations and key milestones, including Phase 3 studies of oral GLP‑1 agonist aleniglipron for chronic weight management, at least through the end of 2028.
Structure Therapeutics Inc. (GPCR) reported a larger quarterly loss as it advanced multiple clinical programs and strengthened its balance sheet. For the three months ended September 30, 2025, net loss was $65,712 with a basic and diluted loss per share of $0.37, compared with a net loss of $33,977 and $0.20 per share a year ago. Operating expenses rose to $73,787, driven by research and development of $58,989 and general and administrative of $14,798. Interest and other income was $8,183.
The company ended the quarter with $799.0 million in cash, cash equivalents and short‑term investments and estimates this will fund projected operations through at least 2027. In September, it sold 3,040,000 ADSs via its ATM program for gross proceeds of approximately $58.5 million and net proceeds of approximately $55.8 million, leaving about $191.5 million capacity. Development highlights include Phase 2b ACCESS studies of aleniglipron (GLP‑1R agonist) with topline data expected by year‑end 2025, advancement of oral amylin receptor agonists (ACCG‑2671 and ACCG‑3535), completion of a Phase 1 study for LTSE‑2578 (LPA1R antagonist), and an asset sale to Exelixis with $10.0 million in initial payments (with $5.2 million received).